Navigation Links
Breckenridge Pharmaceutical to Market Methylphenidate Oral Solution Through Agreement With Tris Pharma (Monmouth Junction, NJ)

BOCA RATON, Fla., July 28 /PRNewswire/ -- Breckenridge announced today that through its agreement with Tris Pharma, the company will market Methylphenidate Solution, the generic version of Methylin® marketed by Shionogi Pharma, Inc., under an Abbreviated New Drug Application (ANDA).  Under the terms of this agreement, the products will be manufactured by Tris Pharma, and marketed and distributed by Breckenridge on an exclusive basis in the U.S.  The companies plan to start shipping immediately. Methylphenidate Oral Solution was filed with a Paragraph IV Certification under Hatch-Waxman and, having "first-to-file status," the companies will enjoy a 180-Day generic exclusivity period granted under the statute. Separately the two companies also have an agreement to market several additional ANDA liquids upon approval by the FDA.

About Breckenridge:

Breckenridge Pharmaceutical is a privately held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of Generic prescription products in many therapeutic categories; including several unique ValuBrand™ products. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 100 products, including multiple ANDA's, in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions and Topical preparations. Breckenridge was recently honored as a 50th Anniversary DIANA award winner for "Best Overall Generic Products Manufacturer" by the HDMA in October 2009.

About Tris Pharma:

Tris Pharma is a privately owned, product-focused, specialty pharmaceutical company engaged in the research and development of innovative drug delivery technologies. Through its OralXR+ platform, Tris has pioneered the delivery of sustained release technology in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' NoBuse™ platform provides abuse-deterrence for opioids and other abuse-prone drugs. The company has more than 20 Rx and OTC products in development with pharmaceutical partners. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey.

Methylin is a registered trademark of Mallinckrodt Inc.

SOURCE Breckenridge Pharmaceutical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Breckenridge Announces Approval of Anastrozole Tablets
2. Topaz Pharmaceuticals Announces Positive Data from Topical Ivermectin Trials Presented at Society of Pediatric Dermatology
3. Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)
4. HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
5. Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010
6. Caraco Pharmaceutical Laboratories, Ltd. Announces G.P. Singh Sachdeva Is Appointed as Chief Operating Officer
7. Foundation Venture Capital Group Sells Interest in Longevica Pharmaceuticals
8. Colorcon Acquires Business of Pharmaceutical Coatings Pvt. Ltd. (India)
9. Onyx Pharmaceuticals Announces Positive Top-Line Carfilzomib Data From Phase 2b Study
10. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide a Clinical Update on Carfilzomib
11. Health Outcomes Data Essential to Biopharmaceutical Sales Process
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... has found that immunotherapy can be efficiently ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Japanese ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and Markets ... "Advanced Wound Care Market by Type (Dressings, Therapy ... User (In-Patient Facility, Out-Patient Facility), and Geography - Global ... --> --> The ... definition and forecast of the global advanced wound care ...
Breaking Medicine Technology:
(Date:11/27/2015)... CO (PRWEB) , ... November 27, 2015 , ... According ... cities are not changing the way that they are handling security in light of ... police and security presence in an attempt to stop an attack from reaching U.S. ...
(Date:11/27/2015)... ... 2015 , ... An inventor, from Hopkinsville, Ky., thought there ... home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. provides ... so, it could help to prevent potential overdose situations. As a result, it ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, ... The digital component is distributed nationally, through a vast social media strategy and ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of the ... 2016, at Caesars Palace in Las Vegas with a pre-conference session on a ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop improving ... only fulfilling the needs of advisers and clients but going above and beyond ... top-tier customer service. However, there's always room for improvement, which is why the ...
Breaking Medicine News(10 mins):